Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 12/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 6/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL478887 | 0.87 | PDPK1 (0.54) | PDPK1GAAKDM4ECYP3A4JAK2 | |
| SCHEMBL16617333 | 0.77 | — | — | |
| SCHEMBL1230771 | 0.77 | CYP1A2 (0.40) | — | |
| SCHEMBL2595676 | 0.77 | MAP2K4 (0.30) | — | |
| SCHEMBL16097285 | 0.74 | — | — | |
| SCHEMBL16616856 | 0.74 | NTRK1 (0.33) | MAP2K1 | |
| SCHEMBL2466230 | 0.74 | JAK2 (0.42) | KDM4EJAK2CDK2JAK3 | |
| SCHEMBL27688056 | 0.74 | JAK2 (0.70) | PDPK1JAK2AURKATGFBR1AURKB | |
| SCHEMBL16617173 | 0.72 | PDE3B (0.33) | — | |
| SCHEMBL3788160 | 0.72 | GRM4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-09-21 | — | — | US | claimed |
| EP-4185588-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | Janssen Pharmaceutica NV (BE) | 2023-05-31 | — | — | EP | claimed |
| CN-116134035-A | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2023-05-16 | — | — | CN | claimed |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | claimed |
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | claimed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | claimed |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | claimed |
| EP-2912037-B1 | 2-AMINOPYRIDINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | claimed |
| US-9926319-B2 | Pyridyl piperidines | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | claimed |
| US-9834541-B2 | 2-aminopyridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-12-05 | — | — | US | claimed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | claimed |
| EP-1841504-A2 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2007-10-10 | — | — | EP | claimed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | claimed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | claimed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2006076575-A2 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | claimed |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | claimed |
| US-6960595-B2 | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | PDPK1 448/4885GAA 430/4885KDM4E 1920/4885 |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | PDPK1 448/4885GAA 430/4885KDM4E 1920/4885 |
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | SERPINC1, F11, TFPI2 | PDPK1 1015/4885GAA 2125/4885KDM4E 1528/4885 |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | TFPI, F3, F12 | PDPK1 1904/4885GAA 2400/4885KDM4E 1669/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | PDPK1 70/4885GAA 2275/4885KDM4E 4152/4885 |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | PDPK1 448/4885GAA 430/4885KDM4E 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.